Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Systematic Review
100%
Visual Acuity
98%
Vitrectomy
84%
Meta-Analysis
77%
Retinal Detachment
73%
Vasculotropin
72%
Best Corrected Visual Acuity
67%
Macular Edema
41%
Polypoidal Choroidal Vasculopathy
38%
Vitreous
32%
Maculopathy
31%
Optical Coherence Tomography
31%
Intravitreal Administration
29%
Proliferative Diabetic Retinopathy
23%
Retinal Pigment Epithelium
23%
Endophthalmitis
22%
Visual Impairment
21%
Agents Acting on the Eye
21%
Cost Benefit Analysis
19%
General Anesthesia
19%
Diabetic Macular Edema
19%
Retinitis pigmentosa
19%
Health Care Cost
19%
Vitreous Hemorrhage
19%
Sclera Buckling Procedure
19%
Ischemic Optic Neuropathy
19%
Retina Vein Occlusion
19%
Macular Hole
19%
Radiation Retinopathy
19%
Uveitis
19%
Choroidal Neovascularization
19%
Brolucizumab
19%
Proliferative Vitreoretinopathy
19%
Dapsone
19%
Pediatrics Patient
19%
Pars Plana Vitrectomy
19%
Wet Macular Degeneration
19%
Recurrence Risk
19%
Age Related Macular Degeneration
19%
COVID-19
19%
Prognostic Factor
19%
Intraocular Foreign Body
19%
Spectral Domain Optical Coherence Tomography
17%
Local Anesthesia
17%
Electroretinography
15%
Odds Ratio
14%
Subretinal Fluid
13%
Recurrent Disease
12%
Candidiasis
12%
Diseases
11%
Keyphrases
Visual Acuity
78%
Indonesia
60%
Vitrectomy
58%
Rhegmatogenous Retinal Detachment
58%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
50%
Clinical Characteristics
42%
Meta-analysis
38%
Systematic Meta-analysis
38%
Macular Edema
38%
General Hospital
38%
Proliferative Vitreoretinopathy
38%
Polypoidal Choroidal Vasculopathy
38%
Intravitreal Injection
29%
Anti-VEGF Therapy
24%
Optical Coherence Tomography
24%
Retinal Detachment
24%
Proliferative Diabetic Retinopathy
24%
Pars Plana Vitrectomy
24%
Retinal pigment Epithelium
23%
Best-corrected Visual Acuity
22%
Multifocal Electroretinogram (mfERG)
22%
Left Eye
22%
Success Rate
22%
Kirana
21%
Subretinal Fluid
21%
Anatomical Outcome
19%
Macula Thickness
19%
Unilateral Retinitis pigmentosa
19%
Encircling Scleral Buckling
19%
Vitreous Hemorrhage
19%
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
19%
Local Anesthesia
19%
Arachidonic Acid Cascade
19%
Cost Analysis
19%
Radiation Retinopathy
19%
General Anesthesia
19%
Diabetic Macular Edema
19%
Central Serous Chorioretinopathy
19%
Myopic Choroidal Neovascularization (mCNV)
19%
Macular Hole
19%
Brolucizumab
19%
Developing Countries
19%
Scleral
19%
Retinal Reattachment
19%
Acute Macular Neuroretinopathy
19%
Unusual Presentation
19%
Dapsone
19%
Leprosy Patients
19%
Neovascular Age-related Macular Degeneration (nAMD)
19%
Patient Characteristics
19%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
69%
Retina Maculopathy
29%
Intravitreal Administration
26%
Macular Edema
24%
Agents Acting on the Eye
24%
Retina Detachment
21%
Visual Impairment
20%
Retina Vein Occlusion
19%
Wet Macular Degeneration
19%
Polypoidal Choroidal Vasculopathy
19%
Recurrence Risk
19%
Central Serous Retinopathy
19%
Subretinal Neovascularization
19%
Brolucizumab
19%
Retinopathy
19%
Dapsone
19%
Diabetic Macular Edema
19%
Age Related Macular Degeneration
19%
Endophthalmitis
19%
Diabetes Mellitus
17%
Bevacizumab
14%
Clinical Trial
13%
Recurrent Disease
12%
Subretinal Fluid
10%
Proliferative Diabetic Retinopathy
9%
Optic Nerve Disease
9%
Adverse Event
9%
Observational Study
8%
Side Effect
8%
Silicone Oil
7%
Diabetic Retinopathy
7%
Inflammation
7%
Diseases
7%
Non-Steroidal Anti-Inflammatory Drug
6%
Pharmacotherapy
6%
Disease Exacerbation
5%
Polypharmacy
5%